InsidersTradesSigma
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
6
Disclosed sells
1
T+90 hit rate
43%
T+90 mean return
-3.9%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Alleva Lawrence M, Director. Officer active across 4 companies, notably Adaptimmune Therapeutics PLC. Aggregated, 17 disclosures have been logged. Split: 6 buys · 1 sell. Total volume traded: €153k. History available since 1 June 2021. The latest transaction was filed on 1 December 2023 (Cession). Regulator: SEC (Form 4). All data is free.
Declarations17 total
2,096 sharesCommon StockSEC:0001553053-26-000002:0
578 sharesCommon StockSEC:0001104659-26-001377:0
84 sharesCommon StockSEC:0001104659-26-001377:1
902 sharesCommon StockSEC:0001562180-24-004753:0
680 shares@ US$88.585100.0% of flowCommon StockSEC:0001562180-23-008013:0
1,087 sharesCommon StockSEC:0001562180-23-005456:0
14,467 shares0Common StockSEC:0001104659-23-070351:0
4,000 shares0Common StockSEC:0000899243-22-026391:0
1,299 sharesCommon StockSEC:0001562180-22-005325:0
671 sharesCommon StockSEC:0001562180-21-004517:0
671 sharesCommon StockSEC:0001562180-21-004517
4,045 shares@ US$8.58870.18% mcap50.0% of flowCommon StockSEC:0000899243-21-021824:0
Ideal exit: 26 Feb 2022 (T+270)
1,035 shares@ US$14.3850.0% of flowCommon StockSEC:0001104659-21-076535:0
Ideal exit: 26 Feb 2022 (T+270)
12,600 shares@ US$0.7950.0% of flowOrdinary Shares with a nominal value of GBP0.001 per shareSEC:0001104659-21-076401:0
Ideal exit: 26 Feb 2022 (T+270)
12,600 shares@ US$0.7950.0% of flowOrdinary Shares with a nominal value of GBP0.001 per shareSEC:0001104659-21-076401
Ideal exit: 26 Feb 2022 (T+270)
1,035 shares@ US$14.3850.0% of flowCommon StockSEC:0001104659-21-076535
Ideal exit: 26 Feb 2022 (T+270)
4,045 shares@ US$8.588750.0% of flowCommon StockSEC:0000899243-21-021824
Ideal exit: 26 Feb 2022 (T+270)
17 of 17 declarations
About Alleva Lawrence M
Lawrence M Alleva is a Board Member at Adaptimmune Therapeutics PLC, Mersana Therapeutics, Inc., and Galera Therapeutics, Inc. He plays a key role in the governance of these biopharmaceutical companies, contributing to strategy development and informed decision-making. His expertise in biotechnology is an asset to the boards.
